QuitFast: Evaluating Transcranial Magnetic Stimulation as a Tool to Reduce Smoking Directly Following a Quit Attempt

Summary

Cigarette smoking constitutes the greatest preventable cause of mortality and morbidity in the US. The most critical period for long term success of smoking cessation appears to be in the first 7 days after the quit date. A metaanalysis of 3 pharmacotherapy trials revealed that abstinence during the first 7 days was the strongest predictor of 6 month outcomes (n=1649; Odds ratio: 1.4, P \<0.0001; Ashare et al. 2013). Prodigious relapse rates during this first week of smoking cessation are likely due to behavioral and neurobiological factors that contribute to high cue-associated craving and low executive control over smoking. The long term goal of the research is to develop evidence-based transcranial magnetic stimulation protocols to facilitate abstinence during this critical period.

Conditions

• Smoking, Cigarette
• Craving
• Addiction
• Nicotine

Interventions

DEVICE

Real cTBS

This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key)

DEVICE

Sham cTBS

This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.

DEVICE

Real iTBS

This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key).

DEVICE

Sham iTBS

This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.

Sponsors & Collaborators

• Virginia Tech Carilion School of Medicine and Research Institute

  collaborator OTHER

• Medical University of South Carolina

  lead OTHER

Principal Investigators

• Colleen A Hanlon, PhD · Medical University of South Carolina

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

70 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2018-09-04

Primary Completion

2019-10-25

Completion

2019-10-25

FDA Device

Yes

Countries

• United States

Study Locations